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5-ﬂuorouracil pharmacokinetics, dihydropyrimidine dehydrogenase-activity and DNA sequence analysis were compared
between a patient with extreme 5-ﬂuorouracil induced toxicity and six control patients with normal 5-ﬂuorouracil related
symptoms. Patients were treated for colorectal cancer and received chemotherapy consisting of leucovorin 20 mg m
72 plus
5-ﬂuorouracil 425 mg m
72. Blood sampling was carried out on day 1 of the ﬁrst cycle. The 5-ﬂuorouracil area under the
curve0?3h in the index patient was 24.1 mg h l
71 compared to 9.8+3.6 (range 5.4–15.3) mg h l
71 in control patients. The
5-ﬂuorouracil clearance was 520 ml min
71 vs 1293+302 (range 980–1780) ml min
71 in controls. The activity of
dihydropyrimidine dehydrogenase in mononuclear cells was lower in the index patient (5.5 nmol mg h
71) compared to the
six controls (10.3+1.6, range 8.0–11.7 nmol mg h
71). Sequence analysis of the dihydropyrimidine dehydrogenase gene
revealed that the index patient was heterozygous for a IVS14+1G4A point mutation. Our results indicate that the
inactivation of one dihydropyrimidine dehydrogenase allele can result in a strong reduction in 5-ﬂuorouracil clearance, causing
severe 5-ﬂuorouracil induced toxicity.
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Fluorouracil (5-FU) is widely used in chemotherapeutic regimens
for the treatment of breast-, colorectal- and head- and neck cancer.
The cytotoxic mechanism of 5-FU is complex, requiring intracellu-
lar bioconversion of 5-FU into cytotoxic nucleotides (see Figure 1).
Inhibition of thymidylate synthase by the metabolite 5-ﬂuoro-2'-
deoxyuridine-5'-monophosphate is thought to be the main
mechanism of cytotoxicity (Pinedo and Peters, 1988) . The cyto-
toxicity is caused by only a small part of the administered 5-FU
dose, as the majority of 5-FU is rapidly metabolised into inactive
metabolites. The initial and rate-limiting enzyme in the catabolism
of 5-FU is dihydropyrimidine dehydrogenase (DPD), catalysing the
reduction of 5-FU into 5,6-dihydroﬂuorouracil (DHFU). Several
groups have suggested a major role of DPD in the regulation of
5-FU metabolism and thus in the amount of 5-FU available for
cytotoxicity (Harris et al, 1990; Fleming et al, 1992a; Lu et al,
1993; Etienne et al, 1994). Indeed, in patients with DPD enzyme
deﬁciency, 5-FU chemotherapy is associated with severe, life-threa-
tening toxicity (Van Kuilenburg et al, 2000a). Moreover, a
markedly prolonged elimination half-life of 5-FU has been
observed in a patient with complete deﬁciency of DPD enzyme
activity (Diasio et al, 1988). Several mutations in the dihydropyri-
midine dehydrogenase gene (DPYD), which encodes for the DPD
enzyme have recently been identiﬁed (Van Kuilenburg et al,
2000a; Collie-Duguid et al, 2000). Furthermore, the frequency of
DPD deﬁciency has been estimated to be as high as 2–3% (Etienne
et al, 1994; Lu et al, 1995; Chazal et al, 1996). To date, a direct
correlation between DPYD gene mutation and decreased 5-FU
clearance has only been suggested but never been proven. In this
study, we provide the ﬁrst detailed analysis of 5-FU pharmacoki-
netics in a patient with low DPD-activity due to heterozygosity
for a mutant allele of the gene encoding DPD.
METHODS
Chemicals
5-Fluorouracil was obtained from Sigma Chemical Co. (Zwijn-
drecht, The Netherlands). 5,6-Dihydro-5-ﬂuorouracil was kindly
provided by Roche Laboratories (Basel, Switzerland). AmpliTaq
Taq polymerase and BigDye-Terminator-Cycle-Sequencing-Ready-
Reaction kit were supplied by Perkin Elmer (San Jose, CA, USA).
A Quaquik Gel Extraction kit was obtained from Qiagen (Hilden,
Germany). Human heparinised plasma was obtained from the Red
Cross Blood Bank (Groningen, The Netherlands). [4-
14C]Thymine
(1.85–2.22 GBq mmol
71) was obtained from Moravek Biochem-
icals (CA, USA) and Lymphoprep (spec.gravity 1.077 g ml
71,
280 mOsm) was from Nycomed Pharma AS (Oslo, Norway).
C
l
i
n
i
c
a
l
Received 6 July 2001; revised 31 December 2001; accepted 22 January
2002
*Correspondence: JG Maring; Department of Pharmacy, Diaconessen
Hospital, PO Box 502, 7940 AM Meppel, The Netherlands;
E-mail: maring@diacmeppel.nl
British Journal of Cancer (2002) 86, 1028–1033
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comLeucosep tubes were supplied by Greiner (Frickenhausen,
Germany). All other chemicals were of analytical grade.
Patient and controls
All patients were treated for Dukes C colorectal cancer and parti-
cipated in a protocol that had been designed to study 5-FU and
DHFU pharmacokinetics. The protocol was approved by the Medi-
cal Ethics Review Committee of the Martini Hospital Groningen
and written informed consent was obtained from all patients. All
patients who entered this protocol were chemotherapy naive.
Chemotherapy consisted of leucovorin 20 mg m
72 combined with
5-FU 425 mg m
72, both on 5 successive days, in a 28-day cycle.
Blood sampling was carried out on the ﬁrst day of the ﬁrst
chemotherapy cycle immediately following the 5-FU dose, adminis-
tered as bolus intravenous injection over 2 min. Leucovorin was
infused after the end of blood sampling. On the following 4 days,
the same 5-FU dose was administered as short time infusion, after
leucovorin administration. One patient experienced severe toxicity
during the ﬁrst chemotherapy cycle and, therefore, a screening on
DPD deﬁciency was initiated. Data from six patients who partici-
pated in the same study protocol and who showed no signs of
severe toxicity were randomly selected for reference pharmacoki-
netics, DPYD genotyping and DPD enzyme activity. These
patients served as controls.
Collection of blood samples
For pharmacokinetic sampling, a canule was placed in the arm of
the patient contralateral from drug administration. Blood samples
(5 ml) were collected in heparinised tubes just before, and 2, 5,
10, 20, 30, 45, 60, 80, 100, 120, 150 and 180 min postinjection.
Collected samples were immediately placed on ice and subsequently
centrifuged at 2500 g for 10 min. The plasma samples were
analysed for 5-FU and DHFU concentrations by high-performance
liquid chromatography (HPLC) on the day of collection. Blood
samples for DPD analysis were collected 5 to 23 months after
blood sampling for 5-FU pharmacokinetics, which corresponds to
intervals ranging from 2 to 17 months after the last 5-FU dose.
None of the patients received chemotherapy at that moment.
Reversed phase HPLC analysis
5-Fluorouracil and DHFU concentrations were measured by HPLC
analysis using a modiﬁcation of the method described by Ackland
et al (1997). Brieﬂy, 100 ml chlorouracil internal standard solution
(80 mg l
71 in water) was added to 1 ml plasma sample, and this
mixture was vortexed and subsequently deproteinated with 50 ml
of a 50% (w v
71) trichloracetic acid solution. After centrifugation
at 8000 g for 2 min the supernatant was transferred into a 20 ml
centrifuge tube and neutralised with 1 ml 1 M sodium acetate solu-
tion. Then 5 ml ethylacetate was added and the mixture was
vortexed during 10 min. After separation of the organic and
aqueous layers by centrifugation at 5000 g for 5 min, the ethylace-
tate layer was transferred into a 10 ml tube and evaporated under a
stream of nitrogen at 258C. The residue was dissolved in 100 ml
ultrapure water and 20 ml was injected. 5-Fluorouracil and DHFU
standards ranging from 0.5 to 20 mg l
71 were prepared in human
plasma. The chromatographic system consisted of a Waters 616
pump equipped with a Waters 717+ autosampler. The separation
of 5-FU and DHFU was accomplished by gradient elution at ambi-
ent temperature on a Phenomenex Prodigy ODS 3 column (I.D.
25064.6 mm, 5 mm) equipped with a guard column (3064.6
mm) of the same material. Mobile phase A consisted of 1.5 mM
K3PO4 and 1% (v v
71) methanol (pH=6.0) and mobile phase B
of 1.5 mM K3PO4 and 5% (v v
71) methanol (pH=6.0).
The gradient was programmed as follows: 100% A during 2 min;
100% A?100% B in 0.5 min; 100% B during 7 min; 100%
B?100% A in 0.5 min; 100% A during 10 min. Detection was
performed using a Waters 996 Photo Diode Array UV detector
interfaced with a Millenium 2010 Chromatography Manager
Workstation. Spectra were acquired in the 201–300 nm range. 5-
FU was monitored at 266 nm and DHFU at 205 nm. The internal
standard chlorouracil was monitored at both wavelengths.
Pharmacokinetic analysis
The pharmacokinetic analyses were performed in the ADAPT II
computer program (version 4.0; USC Los Angeles). The pharmaco-
kinetic data of both the index patient and the six control patients
were tested in eight different models. In each model the patient’s
data were ﬁtted individually and for each data set the Akaike Infor-
mation Criterion (AIC) was calculated. The model with the lowest
summarised AIC value was selected as the better one (data not
shown). The model used for calculating 5-Fluorouracil pharmaco-
kinetics is a two-compartment model with Michaelis–Menten
elimination from the ﬁrst compartment and is described by two
differential equations:
dX1
dt
ÿ 
Vmax
V1km  X1
 k12  kurineX1  k21X2  Rinf
dX2
dt
 k12X1 ÿ k21X2
X1 and X2 indicate the amount of drug in each compartment,
respectively. The k-values represent linear distribution- and elimi-
nation rate constants, and the Vmax and Km values represent
Michaelis–Menten constants for non-linear elimination from the
ﬁrst compartment. Rinf represents the infusion rate of 5-FU.
The area under the curve of 5-FU and DHFU was calculated
using the trapezoid rule. The average systemic clearance of 5-FU
was calculated by dividing the administered dose by the area under
the curve (AUC0?3h).
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Figure 1 Metabolism of 5-FU. 5-Fluoro-2'-deoxyuridine-5'-monophos-
phate (FdUMP) is the cytotoxic product resulting from a multi-step 5-FU
activation route. FdUMP inhibits the enzyme thymidylate synthase (TS),
which leads to intracellular accumulation of deoxy-uridine-monophospate
(dUMP) and depletion of deoxy-thymidine-monophosphate (dTMP). This
causes arrest of DNA synthesis. The initial and rate-limiting enzyme in
the catabolism of 5-FU is dihydropyrimidine dehydrogenase (DPD), catalys-
ing the reduction of 5-FU into 5,6-dihydroﬂuorouracil (DHFU). Subse-
quently, DHFU is degraded into ﬂuoro-b-ureidopropionic acid (FUPA)
and ﬂuoro-b-alanine (FBAL).
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activity
To investigate whether the 5-FU toxicity might have been caused
by a partial deﬁciency of DPD, we determined the activity of
DPD in peripheral blood mononuclear (PBM) cells. Therefore
PBM cells were isolated from 15 ml EDTA anticoagulated blood
and the activity of DPD was determined according previously
described methods (Van Kuilenburg et al, 2000b). In brief, the
sample was incubated in a reaction mixture containing 35 mM
potassium phosphate pH 7.4, 1 mM dithiothreitol, 2.5 mM magne-
sium chloride, 250 mM NADPH and 25 mM [4-
14C]thymine. After
an appropriate incubation time, the reaction catalysed by DPD
was terminated by adding 10% (v v
71) perchloric acid. The reac-
tion mixture was centrifuged at 11000 g for 5 min to remove
protein. The separation of radiolabelled thymine and the reaction
products was performed by reversed phase HPLC. Protein concen-
trations were determined with a copper-reduction method using
bicinchoninic acid, as described by Smith et al (1985).
PCR ampliﬁcation of coding exons
The DNA from the index and control patients was isolated from
PBM cells as previously described (Van Kuilenburg et al, 1997).
PCR ampliﬁcation of exon 14 and ﬂanking intronic regions was
carried out according to Van Kuilenburg et al (2000a). PCR
products were separated on 1% agarose gels, visualised with ethi-
dium bromide and puriﬁed using a Qiaquick Gel Extraction kit
and used for direct sequencing.
Sequence analysis
Sequence analysis of the genomic fragment was carried out on an
Applied Biosystems model 377 automated DNA sequencer using
the Dye-Terminator method.
Statistical analysis
Each value, measured in the index patient, was compared to the
mean+2 s.d. range of the corresponding parameter in the control
group. Values outside this range were considered abnormal
(P50.05). We did not match our control patients for age and
gender.
RESULTS
Clinical evaluation
Patient characteristics from the index and control patients, as
measured before 5-FU administration on the ﬁrst day of the ﬁrst
chemotherapy cycle, are listed in Table 1. The index patient is a
60-year-old white female who received adjuvant chemotherapy
for Dukes C colon carcinoma. She was known with a chronic
moderate renal function impairment as a result of a double-sided
nephrolithotomy at age 40. The ﬁrst two injections with a total
dose of 800 mg 5-FU day
71 were tolerated well by the patient
without complications. On the third day of chemotherapy she
experienced nausea and cold shivers. The nausea was successfully
treated with metoclopramide. The cold shivers remained on days
4 and 5. Twelve days after administration of the ﬁrst 5-ﬂuouracil
injection, leukopenia (1.5610
9 leukocytes l
71) and thrombocyto-
penia (26610
9 platelets l
71) developed along with nausea,
diarrhoea, stomatitis, fever and hair loss. The next day leukocytes
and platelets decreased to 0.5610
9 l
71 and 12610
9 l
71 (both
nadir values respectively). During this period the patient developed
leukopenic fever (408C) for which antibiotics were administered.
Until day 20 the leucocytes and platelets remained low
(1610
9 l
71 and 13610
9 l
71 respectively). During the subsequent
week the clinical picture and hematological parameters gradually
improved and normalised. On day 34 the patient was discharged
from the hospital.
The toxicity observed in the six control patients was limited to
mild nausea (n=4), vomiting (n=2) and CTC grade 1 stomatitis
(n=1).
Pharmacokinetic analysis
The clearance of 5-FU was considerable slower in the index patient
than in the six control patients. In all control patients the plasma
level at t=90 min was below 0.1 mg l
71, whereas in the index
patient the plasma level was still 3.8 mg l
71 at this time point
(see Figure 2). The AUC0?3h in the patient suffering from toxicity
was 24.1 mg h l
71 compared to 15.3 mg h l
71 as highest
AUC0?3h value in control patients. We calculated an average
systemic clearance of only 520 ml min
71 vs 980–1780 ml min
71
in controls. The Vmax value, calculated by pharmacokinetic model-
ling was 548 mg h
71, while the Vmax values of control patients
ranged from 984 to 1772 mg h
71 (see Table 2). The pharmacoki-
netic data of the six control patients were comparable to data from
literature (Port et al, 1991; Terret et al, 2000)
The effect of the impaired renal function of the index patient on
5-FU clearance was studied by pharmacokinetic modelling.
The excretion of 5-FU in urine was measured in ﬁve patients
and kurine was estimated 0.5+0.08 h
71. This kurine value, individu-
ally normalised on calculated GFR, was used during subsequent
modelling of other patient data. A normal renal function was simu-
lated in the index patient by replacing the GFR related kurine by
kurine=0.6.
Renal function impairment appeared to have only a slight effect
on 5-FU clearance. In the index patient, we estimated an additional
18% increase of the AUC due to the renal insufﬁciency upon a
108% higher AUC due to partial DPD deﬁciency.
Simulation of anuria in the control group (Kurine=0), revealed a
16+4% increase of the 5-FU AUC.
Activity of DPD in PBM cells
The activity of DPD in peripheral blood mononuclear (PBM) cells
was lower in the patient experiencing severe toxicity
(5.5 nmol mg
71 h
71) compared to the six control patients (8.0–
11.7 nmol mg
71 h
71; mean 9.6) and comparable to obligate
heterozygotes (Van Kuilenburg et al, 2000a)
Genomic sequence analysis
Sequence analysis of the DPYD gene showed that the patient was
heterozygous for a G?A point mutation in the invariant GT splice
donor site (IVS14+1G4A), leading to the skipping of exon 14
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Table 1 Patient characteristics
Index Controls (n=6)
patient mean+2 s.d.
Gender M/F F 4/2
Age (year) 69 64+12
Weight (kg) 73 77+12
Serum creatinine (mmol l
71) 184
a 81+30
Aspartate aminotransferase (U l
71)2 3 1 8 +8
Alanine aminotransferase (U l
71)4 1 2 9 +26
LDH (U l
71) 379 302+152
Alkaline phosphatase (U l
71)9 5 7 2 +24
Bilirubin total (mmol l
71)7 1 0 +6
Albumin (g l
71)3 2 3 7 +8
aOutside 95% control range, P50.05.
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pre-mRNA splicing.
Sequence analysis of exon 14 of DPYD of the six control patients
revealed no mutations.
DISCUSSION
5-Fluorouracil remains the major drug in the treatment of
advanced colorectal cancer. Dihydropyrimide dehydrogenase is
the key metabolic enzyme in 5-FU degradation and since more
than 80% of the dose is metabolised by this enzyme, DPD activity
is one of the main factors determining drug exposure (Harris et al,
1990; Fleming et al, 1992a; Lu et al, 1993; Etienne et al, 1994). It is
generally accepted that DPD activity in the liver is responsible for
the majority of 5-FU catabolism (Ho et al, 1986; Fleming et al,
1992b), but PBM cells are often used as a surrogate for liver
DPD activity, since these cells are better accessible (Harris et al,
1990; Fleming et al, 1992a; Lu et al, 1993; Etienne et al, 1994).
Several groups have suggested that markedly diminished DPD
activity in PBM cells is strongly related to the risk of developing
severe 5-FU toxicity due to reduced 5-FU clearance (Lu et al,
1993; Etienne et al, 1994; Van Kuilenburg et al, 2000a). Although
total DPD deﬁciency is rare in adults, about 2–3% of the popula-
tion has a low PBM–DPD enzyme level and, thus, is at risk to
develop severe toxicity when treated with 5-FU (Etienne et al,
1994; Lu et al, 1995; Chazal et al, 1996). In only few reports
however, the effect of DPD-deﬁciency on 5-FU clearance has been
objectively quantiﬁed. Diasio et al (1988) administered a test dose
of 25 mg m
72 5-FU to a patient with non-detectable DPD-activity
in PBM cells and found a very low 5-FU clearance rate. This
patient was probably homozygous for a mutant DPD allele,
although the genetic cause was never elucidated. Stephan et al
(1995) reported severe toxicity in a female patient after treatment
comprising Leuvorin 500 mg m
72 as 2 h intravenous infusion plus
125 mg orally, followed by 5-FU 2 g m
72 as a 24 h continuous
infusion. They found a 5-FU plasma level of 0.3 mg l
71 on day
15 after administration, which implies a dramatic overexposure
to 5-FU. This patient could not have been homozygous deﬁcient
because the DPD activity in lymphocytes was within the normal
range. The role of PBM–DPD activity as an indicator for 5-FU
clearance is, however, questionable. Lu et al (1993) found a corre-
lation between PBM–DPD activity and DPD activity measured in
the liver, but others reported a weak, non-signiﬁcant relationship
(Chazal et al, 1996). Both Harris et al (1990) and Fleming et al
(1992a) initially reported a correlation between PBM–DPD activ-
ity and 5-FU clearance but re-examination of this relationship in a
larger set of patients revealed a markedly weakened correlation
(Etienne et al, 1994). These data indicate that PBM-DPD activity
is not a strong and reliable indicator of 5-FU clearance. To some
extent, the variability in DPD activity might have been caused by
the composition of the isolated PBM cells (Van Kuilenburg et al,
2000b). Another important factor is the timing of cell sampling
in relation to 5-FU administration, since McLeod et al (1998)
showed that 5-FU is able to inhibit DPD-activity.
In this paper, we report a combined pharmacokinetic and genet-
ic analysis of the DPYD gene and demonstrate that a single G?A
point mutation in the invariant splice donor site IVS14+1 of the
DPYD gene has profound impact on the clearance of 5-FU. We
also found a lower PBM–DPD activity in the index patient
compared to six controls. The DPD activity was comparable to
the activity observed in obligate heterozygotes
(5.5+2.1 nmol mg
71 h
71, n=8) in previous work (Van Kuilen-
burg et al, 2000a), but the measured value also ﬁts within the
range for normal controls (10.0+3.4 nmol mg
71 h
71, range
3.4–18 nmol mg
71 h
71, n=22). This might indicate that not only
obligate heterozygotes, but also low normal homozygotes are at risk
for developing severe toxicity when treated with 5-FU. It is
however as yet unclear whether the pharmacokinetic proﬁle of 5-
FU is identical in both groups.
We did not measure DPD activity and 5-FU pharmacokinetics
on the same day. DPD activity was measured at least 2 months
after completing chemotherapy and therefore might have been
changed since the ﬁrst chemotherapy cycle as a result of
chemotherapy itself or disease state. Although 5-FU has a direct
inhibitory effect on DPD activity, as was shown by McLeod et al
(1998), we believe that it is not likely that this effect will continue
until 2 months after the last dose. Furthermore, it has been shown
that DPD activity is lower in breast-cancer patients compared to
healthy persons (Lu et al, 1998), suggesting an effect of disease state
on DPD activity. All our patients had Dukes C carcinoma and
showed no signs of disease progression at the time of blood
sampling for DPD. Therefore we considered the index patient
and controls comparable regarding their disease state. Thus, despite
delayed DPD sample collection, we believe our results to be repre-
sentative for DPD activity during pharmacokinetic sampling.
The structural organization of the DPYD gene has recently been
described. It is 150 kb in length and consists of 23 exons ranging in
size from 69 to 1404 bp (Johnson et al, 1997). The G?A mutation
changes an invariant GT splice donor site into AT which leads to
skipping of a 165 bp exon immediately upstream of the mutated
spice donor site during the splicing of DPD pre-mRNA. As a
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Table 2 Overview of pharmacokinetic parameters. Data are presented
as single observation or as mean+2 s.d.
Index patient Controls
Kurine=0.6 Kurine=0
Index simulated Controls simulated
patient data (n=6) data
Dose (mg m
72) 447 431+64
AUC 5-FU (mg h l
71) 24.1
a 20.4
a 10.0+6.6
a 11.8+8.6
a
CI 5-FU (ml min
71) 553
a 637
a 1493+840
a 1306+886
Vmax (h
71) 548
a 1329+680
a
V1 kg
71 (l) 0.25 0.23+0.06
K12 (h
71) 9.0 5.1+7.6
K21 (h
71) 7.5 5.2+6.6
aData of index patient outside 95% control range, P50.05.
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Figure 2 Pharmacokinetics of 5-FU. Shown are 5-FU plasma levels
observed in a patient with a IVS14+1G4A mutation in the DPYD gene
(solid diamond) and the 5-FU plasma levels resulting from simulation of a
normal renal function in the same patient. 5-FU plasma levels from control
patients are depicted as mean+s.d. (solid triangle; n=6).
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581–635 of the primary sequence of the DPD protein is lacking in
the mature DPD mRNA, which results in an enzyme without cata-
lytic activity (Wei et al, 1996; Van Kuilenburg et al, 1997). Analysis
of the prevalence of the various mutations among cancer patients
with partial DPD deﬁciency showed that the G?A mutation in
the invariant splice donor site is the most common one (43%)
(Van Kuilenburg et al, 2000a). The prevalence of this mutation
in the normal Dutch population is 1.8% (Van Kuilenburg et al,
2001).
We believe that in our patient the IVS14+1G4A mutation
explains the dramatic reduction in 5-FU clearance compared to
controls. This is in line with the observation that at least 80% of
the 5-FU dose is catabolised by DPD. Although our patient had
a moderately impaired renal function, we analysed that the effect
of renal function on 5-FU clearance is only limited. This was to
be expected, as only about 10% of the 5-FU dose is normally
excreted in urine (Heggie et al, 1987). It is important, however,
to realise that in patients with reduced DPD capacity, the contribu-
tion of renal excretion to total clearance is relatively increased. As a
consequence, the impact of renal insufﬁciency on the AUC is larger
in DPD deﬁcient than in normal patients. Thus, in the index
patient, the impaired renal function might have contributed to
development of more severe toxicity, additionally to that caused
by DPD deﬁciency.
Development of rapid assays to detect mutations in the DPYD
gene makes it possible to carry out a genetic screening prior to
the start of chemotherapy containing 5-FU. However, it is impor-
tant to identify those mutations that result in a defect DPD
protein. So far, 19 molecular defects in the DPYD gene such as
point mutations and deletions due to exon skipping have been
reported, but not all mutations result in a DPD enzyme deﬁciency
(Van Kuilenburg et al, 2000a). Incomplete correlation between
DPD phenotype and genotype is clinically important and suggests
that DPD polymorphisms are likely to be complex (Collie-Duguid
et al, 2000).
Our results indicate that low DPD activity, due to the inactiva-
tion of one DPYD allele results in a strong reduction in 5-FU
clearance, measured on the ﬁrst chemotherapy day. Inhibition of
the yet reduced DPD activity by 5-FU itself during subsequent days
may lead to further reduction of 5-FU clearance and this may
further add to the development of severe toxicity. In order to iden-
tify those mutations that result in reduced 5-FU clearance,
monitoring of 5-FU plasma levels using a limited sampling strategy
can be helpful in patient selection. This requires, however, rapid
plasma level analysis, because results from the ﬁrst 5-FU infusion
must be available before the second dose is administered. Unfortu-
nately, no rapid 5-FU (immuno-)assay is available yet, and
therefore in most hospitals therapeutic drug monitoring of 5-FU
is not yet feasible.
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